Immunosuppression in human peripheral blood T lymphocytes by fluvastatin

Acta Biochimica et Biophysica Sinica

Volumn 36, Issue 10, 2004, Pages 649-655

  Wu, Li Hua ^a   Wan, Yun Le ^b   Xie, Hai Yang ^a   Zhang, Wen Jin ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cytokine; Fluvastatin; Nuclear factor of activated T lymphocytes; T cell activation; T cell proliferation

Indexed keywords

CD69 ANTIGEN; CYCLOSPORIN A; FLUINDOSTATIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; LOW DENSITY LIPOPROTEIN;

ARTICLE; BIOASSAY; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KILLER CELL; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 10044257849     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: 10.1093/abbs/36.10.649     Document Type: Article

References (25)

1. Ornish D. Statins and the soul of medicine. Am J Cardiol, 2002, 89(11): 1286-1290
2. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-1. J Clin Invest, 2001, 107(11): 1423-1432
3. Kwak BR, Mulhaupt F, Mach F. Atherosclerosis: Anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev, 2003, 2(6): 332-338
4. Mach F. Statins as immunomodulators. Transpl Immunol, 2002, 9(2-4): 197-200
5. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res, 2003, 9(1): 10-19
6. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology, 1996, 34(1): 51-61
7. Katznelson S, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Terasaki PI et al. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant, 1998, 17(4): 335-340
8. Hillyard DZ, Cameron AJ, McIntyre AH, Hadden MH, Marshall HE, Johnston N, Jardine AG. Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharmacol Physiol, 2002, 29(8): 673-678
9. Murphy LL, Hughes CC. Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: Involvement of the Wnt/ glycogen synthase kinase-3 beta pathway. J Immunol, 2002, 169(7): 3717-3725
10. Wanner C, Quaschning T. Abnormal lipid metabolism after renal transplantation. Ann Transplant, 2001, 6(1): 5-8
11. Kirklin JK, Benza RL, Rayburn BK, McGiffin DC. Strategies for minimizing hyperlipidemia after cardiac transplantation. Am J Cardiovasc Drugs, 2002, 2(6): 377-387
12. Holdaas, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet, 2003, 361(9374): 2024-2031
13. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Krobot K, Steinbeck G et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation, 2003, 107(1): 93-97
14. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med, 2000, 6(12): 1399-1402
15. Muldoon MF, Flory JD, Marsland A, Manuck SB, Whiteside TL, Rabin B. Effects of lovastatin on the immune system. Am J Cardiol, 1997, 80(10): 1391-1394
16. Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-Margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol, 2000, 199(1): 15-24
17. Gao ZH, Lazarovits AI, Wang J, Xing J, Garcia B, Kellersmann R, Kelvin D et al. Allograft tolerance induced by cyclophosphamide without prior inoculation of donor cells - immune suppression and redirection. Transpl Immunol, 2000, 8(1): 65-73
18. Dorado B, Jerez MJ, Flores N, Martin-Saavedra FM, Duran C, Ballester S. Autocrine IL-4 gene regulation at late phases of TCR activation in differentiated Th2 cells. J Immunol, 2002, 169(6): 3030-3037
19. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature, 2002, 420(6911): 78-84
20. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H, Fujita T et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res, 2003, 93(10): 948-956
21. Peng SL, Gerth AJ, Ranger AM, Glimcher LH. NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity, 2001, 14(1): 13-20
22. Katzav S. Vav1: an oncogene that regulates specific transcriptional activation of T cells. Blood, 2004, 103(7): 2443-2451
23. Yu CR, Mahdi RM, Ebong S, Vistica BP, Gery I, Egwuagu CE. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J Biol Chem, 2003, 278(32): 29752-29759
24. Anderson P, Sundstedt A, Li L, O'Neill EJ, Li S, Wraith DC, Wang P. Differential activation of signal transducer and activator of transcription STAT3 and STAT5 and induction of suppressors of cytokine signalling in Th1 and Th2 cells. Int Immunol, 2003, 15(11): 1309-1317
25. Fujimoto M, Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol, 2003, 24(12): 659-666